Kaynaklar

• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26: 649–666.
   PubMed Web of Science ®Google Scholar
• Storch EA, Lehmkuhl H, Geffken G, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 2008; 25: 172–174.
   Web of Science ®Google Scholar
• Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165: 1432–1441.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12: 683–689.
   Web of Science ®Google Scholar
• Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70: 756–764.
   PubMed Web of Science ®Google Scholar
• Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009; 19: 265–274.
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009; 23: 511–521.
   PubMed Web of Science ®Google Scholar
• Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008; 18: 197–205.
   PubMed Web of Science ®Google Scholar
• Curtis AR, Richards RW. The Treatment of Psychogenic Excoriation and Obsessive Compulsive Disorder Using Aripiprazole and Fluoxetine. Ann Clin Psychiatry 2007; 19: 199–200.
   Google Scholar
• Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005; 20: 603–610.
   PubMed Web of Science ®Google Scholar
• Akdemir A, Örsel SD, Dağ İ ve ark. Hamilton Depresyon Derecelendirme Ölçeğinin geçerliliği-güvenilirliği ve klinikte kullanımı. 3P (Psikiyatri Psikoloji ve Psikofarmakoloji) Dergisi 1996; 4: 251–259.
   Google Scholar
• Karadağ F, Oral ET, Yalçın FA ve ark. Young Mani Derecelendirme Ölçeğinin Türkiye'de geçerlik ve güvenirliği. Türk Psikiyatri Dergisi 2002; 13: 107–114.
   PubMedGoogle Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services Publication (ADM) 1976: 218–222.
   Google Scholar
• Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233.
   Web of Science ®Google Scholar
• Endicott J, Spitzer R, Fleiss J, Cohen J. The global assessment scale. Arch Gen Psychiatry 1976; 33: 766–771.
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 789–812.
   Web of Science ®Google Scholar
• Erol N, Şimşek Z. Türkiye Ruh Sağlığı Profili: Çocuk ve Gençlerde Ruh Sağlığı:Yeterlik alanları, davranış ve duygusal sorunların dağılımı. Türkiye Ruh Sağlığı Profili Raporu, T.C. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü Erol N, Kılıç C, Ulusoy M, Keçeci M, ve Şimşek Z (Editörler) Ankara: Eksen Tanıtım Ltd., 1998: 25–75.
   Google Scholar
• Yücelen AG, Rodopman-Arman A, Topçuoğlu V, Yazgan MY, Fisek G. Interrater reliability and clinical efficacy of Children's Yale-Brown Obsessive-Compulsive Scale in an outpatient setting. Compr Psychiatry 2006; 47: 48–53.
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectrum. 2007; 12: 683–689.
   Web of Science ®Google Scholar
• Tramontina S, Zeni CP, Pheula GF, De Souza CK, Rohde LA. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectrum. 2007; 12: 758–762.
   PubMed Web of Science ®Google Scholar
• Werner C, Nyilas M, Forbes RA, Jin N, Johnson B, Owen R, et al. Long-term efficacy and safety of aripiprazole in pediatric patients with bipolar I disorder. Poster presented at the XXVIth Congress Collegium Internationale Neuro-Psychopharmacologicum, 2008, Munich, Germany.
   Google Scholar
• Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara NK, Stansbrey RJ. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18: 347–354.
   PubMed Web of Science ®Google Scholar
• Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009; 23: 511–521.
   PubMed Web of Science ®Google Scholar
• Kültür SEÇ, Tiryaki A, Taşgın E. Zekâ geriliğinde görülen davranış sorunları için aripiprazol: Olgu bildirimleri. Klinik Psikofarmakoloji Bülteni -Bulletin of Clinical Psychopharmacology 2009; 19: 293–296.
   Google Scholar
• Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R. Aripiprazole monotherapy in non-psychotic bipolar I depression, J Clin Psychopharmacol 2008; 28: 13–20.
   PubMed Web of Science ®Google Scholar
• Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. Serotoninergic mechanisms in the treatment of obsessive- compulsive disorder. Drug Discov Today 2008; 13: 325–332.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo, controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794–801.
   PubMed Web of Science ®Google Scholar
• Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004; 65 (Suppl 14): S11–S17.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential Psychopharmacology-Neuroscientific Basis and Practical Applications. 2. Baskı, New York: Cambridge University Press, 2000.
   Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, and Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115–119.
   PubMed Web of Science ®Google Scholar
• Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders. J Clin Psychiatry 2006; 64; 1327–1340.
   Google Scholar
• Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive. Am J Psychiatry 1993; 150: 819–821.
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622–632.
   PubMed Web of Science ®Google Scholar
• Marcus RN, Owen, R, Kamen L, Manos G, McQuade RD, Carson, WH, Aman MG. A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1110–1119.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601.
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 2007; 68 (suppl. 4): S34–S39.
   Google Scholar
• U.S. Food and Drug Administration (FDA), www.accessdata.fda.gov/drugsatfda_docs/label/2005/021713s004,021436s007lbl.pdf - 2009.
   Google Scholar
• Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 2004; 493: 75–83.
   PubMed Web of Science ®Google Scholar
• Gibson AP, Crismon ML, Mican LM, Fischer C. Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. Int Clin Psychopharmacol. 2007; 22: 101–105.
   PubMed Web of Science ®Google Scholar